| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 05/31/2000 | CN1255133A 1,5-dihydro-pyrazolo [3,4-D]-pyrimidinone derivatives |
| 05/31/2000 | CN1255062A Use of quinazoline compounds for the treatment of polycystic kidney disease |
| 05/30/2000 | US6069156 Indole derivatives as cGMP-PDE inhibitors |
| 05/30/2000 | US6069152 Nervous system disorders; cardiovascular disorders; gastrointestinal disorders |
| 05/30/2000 | US6069006 Connective tissue growth factor (CTGF) regulatory nucleic acid sequences |
| 05/30/2000 | US6068983 Introducing into cells a dna molecule coding for an fc receptor which is then expressed for increased phagocytic activity; combating infection and/or modulating immune complex disease |
| 05/30/2000 | US6068845 Inhibitory activity on the abnormal production of extracellular matrices in dermal fibroblasts activated with tranforming growth factor beta by administering the plant extract of a plant belonging to the genus sophora |
| 05/25/2000 | WO2000029846A2 COMPOSITIONS AND METHODS RELATING TO THE PEROXISOMAL PROLIFERATOR ACTIVATED RECEPTOR-α MEDIATED PATHWAY |
| 05/25/2000 | WO2000029583A2 Immunoglobulin superfamily proteins |
| 05/25/2000 | WO2000029422A1 31 human secreted proteins |
| 05/25/2000 | WO2000029405A1 Method for preparing (2s)-1-[ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide |
| 05/25/2000 | WO2000029384A1 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| 05/25/2000 | WO2000029381A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | WO2000029379A1 1-aminoethylquinoline derivatives for treating urinary incontinence |
| 05/25/2000 | WO2000029371A1 Excitatory amino acid receptor modulators |
| 05/25/2000 | WO2000028983A1 Novel 4-dedimethy laminotetra cycline derivatives |
| 05/25/2000 | WO2000012049A3 A method for the treatment of staphylococcal disease |
| 05/25/2000 | DE19853278A1 New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis |
| 05/25/2000 | CA2351187A1 Tetrahydroisoquinoline derivatives as lhrh antagonists |
| 05/25/2000 | CA2350785A1 31 human secreted proteins |
| 05/25/2000 | CA2350532A1 Excitatory amino acid receptor modulators |
| 05/25/2000 | CA2350443A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | CA2349618A1 Compositions and methods relating to the peroxisomal proliferator activated receptor-.alpha. mediated pathway |
| 05/25/2000 | CA2348676A1 Method for preparing (2s)-1-¬ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl| pyrrolidine-2- carboxamide |
| 05/24/2000 | EP1002797A1 4,5-DIHYDRO- 1H]-BENZ g]INDAZOLE-3-CARBOXYLIC ACID DERIVATIVES |
| 05/24/2000 | EP1002791A1 Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis |
| 05/24/2000 | EP1002074A1 Calcium-binding phosphoprotein |
| 05/24/2000 | EP1001984A1 NOVEL ESTROGEN RECEPTOR $g(b) AND ISOFORMS |
| 05/24/2000 | EP1001983A1 NOVEL ESTROGEN $g(b) RECEPTOR AND ISOFORMS |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001970A1 Dipeptide derivatives as growth hormone secretagogues |
| 05/24/2000 | EP1001797A1 Soya extract, process for its preparation and pharmaceutical composition |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1052725C Tricyclic vasopressin antagonists |
| 05/24/2000 | CN1052723C Bicyclic aromatic compounds as therapeutic agents, its preparing method and drug composition containing said compound |
| 05/24/2000 | CN1052655C Human relaxin formulation |
| 05/23/2000 | US6066735 Treatment of erectile dysfunction |
| 05/23/2000 | US6066717 RsbW-1 protein |
| 05/23/2000 | US6066643 Administering to said mammal an effective amount of moxonidine, or a pharmaceutically acceptable salt thereof |
| 05/23/2000 | US6066502 Endothelin converting enzyme (ECE) |
| 05/23/2000 | US6066324 Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles |
| 05/18/2000 | WO2000028323A1 Methods for identifying modulators of bs69 activity |
| 05/18/2000 | WO2000028045A2 Human hydrolase proteins |
| 05/18/2000 | WO2000027868A2 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | WO2000027845A1 Spiro-indolines as y5 receptor antagonists |
| 05/18/2000 | WO2000027819A2 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | WO2000027815A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |
| 05/18/2000 | WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 05/18/2000 | WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | WO2000027414A2 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | WO2000027395A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 05/18/2000 | WO2000027383A1 Dysuria remedies |
| 05/18/2000 | WO2000027377A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | WO2000027364A1 New controlled release bead, a method of producing the same and multiple unit formulation comprising it |
| 05/18/2000 | WO2000008141A3 Short oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | WO2000008140A3 Antisense oligonucleotides for the inhibition of vegf expression |
| 05/18/2000 | CA2350714A1 Spiro-indolines as y5 receptor antagonists |
| 05/18/2000 | CA2350388A1 Human hydrolase proteins |
| 05/18/2000 | CA2350211A1 Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts |
| 05/18/2000 | CA2350208A1 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | CA2350182A1 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | CA2349498A1 Methods and compositions for treating or preventing peripheral neuropathies |
| 05/18/2000 | CA2348934A1 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | CA2347916A1 Inhibition of the formation of vascular hyperpermeability |
| 05/17/2000 | EP1000927A2 Excitatory amino acid receptor modulators |
| 05/17/2000 | EP1000621A2 Use of 6-heterocyclic-4-amino-1,3,4,5-tetrahydrobenz (CD) indoles for treating motion sickness and vomiting |
| 05/17/2000 | EP1000144A2 Lactoferrin receptor genes of moraxella |
| 05/17/2000 | EP1000062A1 Tricyclic vasopressin agonists |
| 05/17/2000 | EP1000059A1 Tricyclic vasopressin agonists |
| 05/17/2000 | EP1000051A1 Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/17/2000 | EP1000048A1 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 05/17/2000 | EP1000047A1 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring |
| 05/17/2000 | EP1000046A1 Piperazine derivatives active on the lower urinary tract |
| 05/17/2000 | EP1000045A1 1,4-disubstituted piperazines |
| 05/17/2000 | EP1000044A1 Benzothia(oxa)diazol derivatives and their use as endothelin-receptor antagonists |
| 05/17/2000 | EP1000039A1 Substituted quinazoline derivatives and their use as tyrosine kinase inhibitors |
| 05/17/2000 | EP1000035A1 Substituted 6-phenylphenanthridines |
| 05/17/2000 | EP1000034A1 Substituted 6-alkylphenanthridines |
| 05/17/2000 | EP1000017A1 Il-8 receptor antagonists |
| 05/17/2000 | EP0999842A1 Novel substituted imidazole compounds |
| 05/17/2000 | EP0999836A1 A pharmaceutical composition active in reducing production of mcp-1 protein |
| 05/17/2000 | CN1253561A Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3', 5'-monophosphate phosphodiesterase (cGMP PDE5) for treatment of sexual dysfunction |
| 05/17/2000 | CN1253560A Sulfonamides for treatment of endothelin-mediated disorders |
| 05/17/2000 | CN1253559A Sulfonyl divalent aryl alpha-hydroxamic acid compounds |
| 05/17/2000 | CN1253501A IL-8 receptor antagonists |
| 05/17/2000 | CN1253474A Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds |
| 05/17/2000 | CN1253004A Process for preparing medicine to treat prostatic diseases |
| 05/17/2000 | CN1252992A Carboprost methylate preparation able to be absorbed via oral mucosa and its preparing process |
| 05/16/2000 | US6063797 γ-RAR antagonist ligand or α-RAR agonist ligand as an apoptosis inhibitor |
| 05/16/2000 | US6063620 Type I angiotensin II receptor specific monoclonal antibodies and hybridomas |
| 05/16/2000 | CA2215020C Tetrazolyl-substituted quinuclidines as substance p antagonists |
| 05/11/2000 | WO2000026252A1 Compounds with growth hormone releasing properties |
| 05/11/2000 | WO2000026245A2 Human membrane transport proteins |
| 05/11/2000 | WO2000026227A1 Ldl related protein and uses thereof |
| 05/11/2000 | WO2000026224A2 Novel macrolide antibiotics |
| 05/11/2000 | WO2000026208A1 N-oxides of heterocyclic compounds with tnf and pde-iv inhibiting activity |
| 05/11/2000 | WO2000026205A1 Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level |
| 05/11/2000 | WO2000026203A1 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 05/11/2000 | WO2000026202A1 2-amino-thiazole derivatives, process for their preparation, and their use as antitumor agents |